Brian Cheng
Stock Analyst at JP Morgan
(2.26)
# 2,663
Out of 5,182 analysts
77
Total ratings
42.86%
Success rate
-2.03%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Downgrades: Neutral | $18 → $13 | $12.81 | +1.48% | 6 | Mar 24, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $95 → $106 | $103.78 | +2.14% | 7 | Mar 19, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $27 | $5.11 | +428.38% | 1 | Mar 4, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $29 | $9.90 | +192.93% | 1 | Mar 2, 2026 | |
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $33.53 | +37.19% | 1 | Feb 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $92 → $122 | $99.12 | +23.08% | 2 | Feb 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $85.40 | +46.37% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.14 | - | 1 | Nov 20, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $13.13 | -61.92% | 5 | Nov 7, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $25.80 | -10.85% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.48 | - | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.35 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $3.06 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $24.50 | +34.69% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $67.48 | -30.35% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $28.33 | -29.40% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $49.51 | +41.39% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.94 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $21.84 | +0.73% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $27.32 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.67 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $8.87 | +272.04% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.35 | +344.44% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.13 | +10,636.20% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.78 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $6.98 | +1,275.36% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.86 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.37 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $8.03 | +958.53% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $9.02 | +132.82% | 1 | Aug 3, 2021 |
Xencor
Mar 24, 2026
Downgrades: Neutral
Price Target: $18 → $13
Current: $12.81
Upside: +1.48%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $95 → $106
Current: $103.78
Upside: +2.14%
Protara Therapeutics
Mar 4, 2026
Initiates: Overweight
Price Target: $27
Current: $5.11
Upside: +428.38%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $29
Current: $9.90
Upside: +192.93%
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $33.53
Upside: +37.19%
Revolution Medicines
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $99.12
Upside: +23.08%
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $85.40
Upside: +46.37%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $13.13
Upside: -61.92%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $25.80
Upside: -10.85%
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.48
Upside: -
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.35
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.06
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $24.50
Upside: +34.69%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $67.48
Upside: -30.35%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $28.33
Upside: -29.40%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $49.51
Upside: +41.39%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.94
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $21.84
Upside: +0.73%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $27.32
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.67
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $8.87
Upside: +272.04%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.35
Upside: +344.44%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.13
Upside: +10,636.20%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.78
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $6.98
Upside: +1,275.36%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $0.86
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.37
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $8.03
Upside: +958.53%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $9.02
Upside: +132.82%